It is very heterogeneous, and, based on hormone receptor (ER and PR) and HER2 (ERBB2) status, can be clinically divided into luminal ER-positive and PR-positive, and further subdivided into luminal A and B, HER2-positive and triple negative breast cancer (TNBC) [1]. This evidence concerns the gene PGR and triple-negative breast carcinoma.